Summit Therapeutics announced updated, extended follow-up data from its Phase 3 HARMONi study for ivonescimab, showing a stronger overall survival advantage in lung cancer patients. This positive data strengthens the drug's profile as it awaits FDA approval, potentially boosting investor confidence.
Summit Therapeutics released updated overall survival data for its lead cancer drug, ivonescimab, from the Phase 3 HARMONi study. The extended follow-up revealed a stronger hazard ratio of 0.76 for Western patients, indicating a more significant survival advantage than previously observed, aligning with results from Asian patients. This positive development is crucial as the company awaits an FDA decision on its Biologics License Application, with a target action date of November 14, 2026. For traders, this strengthens the investment case for SMMT in the short term due to increased confidence in the drug's efficacy and long-term potential if approved, but regulatory approval remains a key risk.